Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (October 2024)
19 slides from Rhythm Biosciences's investor presentation, Oct 24, 2024
Slide 1: Market Presentation
Market Presentation 24 OCTOBER 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Executive Summary
Executive Summary • Rhythm Biosciences is developing and commercialising novel clinical cancer diagnostics. Overview • ColoSTAT® is a 2nd generation multiplex assay designed to detect bowel cancer in a patient blood sample that is in the final stages of development ahead of commercialisation in 2025
Slide 4: Why Rhythm Biosciences?
Why Rhythm Biosciences? Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology. Developing novel screening solutions for specific cancers via patient friendly blood tests is our primary focus. Patent protected; fully charact
Slide 5: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY 2 1.8 Share Price (at 23 Oct 2024) $0.11 1.6 1.4 Shares on Issue 248.5M 1.2 1 Unlisted Options 21M 0.8 0.6 Market Capitalisation $27.35M 0.4 Top 20 Shareholders 42% 0.2 0 09 Nov 09 Arp 09 Sep 09 Feb 09 Jul 09 Dec 09 May 0
Slide 6: Our Clinical Advisory Board
Our Clinical Advisory Board Sally Prof Prof Benton Jon Emery Finlay Macrae Consultant Clinical Biochemist and Herman Professor of Primary Care Cancer Head of Colorectal Medicine and Genetics at Clinical Lead for Clinical and Specialist Research at the University of Melbourne, and The Royal Melbourne
Slide 7: Cancer is an increasing burden on global healthcare systems
Cancer is an increasing burden on global healthcare systems Detecting and diagnosing cancer remains critical to public health Estimated % rise in all cancers 2022 to 2050 Estimated number of worldwide prevalent cases in 5 Males and Females, Age 0-85+ years from 2022 RHY focus Breast 8.2m Colorectu
Slide 8: Colorectal cancer (CRC) is the 2nd leading cause of cancer death globally
Colorectal cancer (CRC) is the 2nd leading cause of cancer death globally CRC is a progressive disease in which epithelial cells GLOBAL BURDEN IN 2020 in the colon or rectum grow out of control² 1.93 million new cases Adenoma ~940,000 deaths¹ Stage 0 RANK: MOST ESTIMATED NEW DEATHS FROM COMMON CANCE
Slide 9: When diagnosed early, CRC can be successfully treated
When diagnosed early, CRC can be successfully treated Disease stage at diagnosis is the key predictor of survival in patients with CRC Missed detection of early-stage CRC results in poor survival rates Diagnoses at Stage I or II only represent Stage at less than half of all CRCs diagnosed in: diagno
Slide 10: Participation in CRC screening programs needs improvement
Participation in CRC screening programs needs improvement Based on current participation rates to CRC screening, Addressable 33–56% of the eligible population across Population Addressable Australia, Europe, UK and US remains unscreened. 45.1 million†† Population Participation rates in CRC screening
Slide 11: Blood tests, such as ColoSTAT, are preferred by patients over stool-based tests
Blood tests, such as ColoSTAT ®, are preferred by patients over stool-based tests currently used in screening Blood-based tests are preferred over faecal tests (FIT) by 78–93% of people who are offered CRC testing, with ease and convenience being the main reasons for their preference In an observati
Slide 12: There are >250 million people who could benefit from an improved blood test
There are >250 million people who could benefit from an improved blood test UNSCREENED % OF TOTAL SCREENING POPULATION/ INCIDENCE OF CRC ADDRESSABLE MARKET POPULATION AGE – SCREENING POPULATION SCREENING METHOD PARTICIPATION RATE OPPORTUNITY (cases per year) MARKETS Europe (EU-27) 746.4 m 231.0 m (5
Slide 13: First major clinical performance evaluation
First major clinical performance evaluation Prospective, multi-centre study to evaluate the clinical performance of the first generation ColoSTAT® for the detection of CRC¹ STUDY DESIGN PRIMARY ENDPOINT Blood-based assay The primary endpoint was to evaluate ColoSTAT® performance compared to N= 989 p
Slide 14: Second generation ColoSTAT clinical assay
Second generation ColoSTAT® clinical assay: Standardised, simpler, faster turnaround time and lower cost Multiplex Planar – Five Plates to a Single Plate Based ELISA (Five reagents to a single kit) Reduced Cost Materials, Packaging and Transport Reduced Chance of Human Error Embraces Increased Autom
Slide 15: Cancer diagnostic interventions
Cancer diagnostic interventions Multiple Diagnostic decisions support an individual through the patient journey MONITORING & MINIMAL RESIDUAL SCREENING DISEASE DETECTION Surveillance PHARMA- COGENOMICS Detection & DRUG TRIAGE SELECTION PHASES Drug Therapy OF DISEASE Diagnosis Surgical SURGICAL Thera
Slide 16: General population screening for CRC remains the ultimate goal
General population screening for CRC remains the ultimate goal Targeting “intermediate” applications represent valuable intermediate steps towards the end goal TECHNICAL COMPLEXITY ‘Intermediate’ Means • Higher prevalence of cancer. SCREENING • Greater flexibility CONFIRMATION / TRIAGE around curren
Slide 17: Upcoming value inflection points
Upcoming value inflection points ESTIMATED DELIVERY ITEM DESCRIPTION DATE Alpha Assay Ready Arrival of Alpha kits for testing Beta Release Candidate Beta Kits ready for verification 2H CY24 Kit Validation Ready Kit Verification completion, Production Kits Ready. 1H CY25 Commercialisation Partner’s I
Slide 18: Platform technology expansion pipeline
Platform technology expansion pipeline Biomarker analysis complete in significant patient sample study for 3 major cancers STAGE 1 STAGE 2 STAGE 3 STAGE 4 STAGE 5 INITIATION FORMULATION DESIGN & FINAL Product Launch Opportunity and Concept and DEVELOPMENT VALIDATION & Post-Launch Risk Analysis Feasi
Slide 19: Conclusion
Conclusion Overview Final stages of developing a potential “blockbuster” diagnostic product targeting a multi-$billion global market. Key Investment An attractive and comparatively simple investment proposition / business model. Highlights Transformed A business with huge potential that has gone thr
Rhythm Biosciences — Investor Presentation (October 2024) on 6ix